ALX Oncology Holdings Inc. (ALXO) - 10-K Summary
Business Context and Reporting Period
Company: ALX Oncology Holdings Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: ALX Oncology is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies. Its pipeline centers on two primary candidates: evorpacept, a CD47 blocker designed to avoid hematologic toxicities, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC). The company has no approved products and generates no product revenue.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Loss | $(101.7) million | $(134.9) million | 25% Decrease |
| Research & Development Expenses | $(77.0) million | $(116.4) million | 34% Decrease |
| General & Administrative Expenses | $(23.9) million | $(26.1) million | 9% Decrease |
| Impairment Charge | $(3.2) million | $0 | New Charge |
| Cash, Cash Equivalents & Investments | $48.3 million | $131.3 million | Significant Decrease |
| Accumulated Deficit | $(722.8) million | $(621.1) million | N/A |
| Term Loan Outstanding | $9.6 million | $9.9 million | Minimal Change |
Note: The company reported no revenue for the period. Expenses decreased primarily due to a reduction in workforce and pipeline prioritization.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 27% ($38.4 million) compared to 2024. This was driven by a 34% drop in R&D expenses (due to reduced clinical manufacturing costs and stock-based compensation following a workforce reduction) and a 9% drop in G&A expenses.
- Impairment Charge: The company recorded a $3.2 million impairment charge in 2025 related to long-lived assets (right-of-use assets and leasehold improvements) in Palo Alto, following a decision to sublease the property. No such charge existed in 2024.
- Liquidity Position: Cash and investments declined significantly from $131.3 million in 2024 to $48.3 million in 2025, reflecting operational burn and lower interest income ($4.0 million vs. $9.4 million in 2024).
- Subsequent Financing: In February 2026 (post-period), the company completed a registered offering raising approximately $140.4 million in net proceeds.
Guidance, Outlook, and Risks
Clinical Progress & Strategy:
- Evorpacept: The company is prioritizing the ASPEN-09-Breast trial (HER2+ breast cancer), which was amended to a single-arm design based on CD47 expression. The ASPEN-06 gastric cancer program will not pursue a U.S. registrational Phase 3 path due to resource allocation; the company is exploring partnerships for this indication. Biomarker analysis identified CD47 overexpression as a key predictor of response.
- ALX2004: The Phase 1 trial for this EGFR-targeted ADC began dosing in August 2025 and has cleared the second dose cohort with no dose-limiting toxicities observed.
Liquidity Outlook:
- Management believes existing cash, investments, and the net proceeds from the February 2026 offering ($140.4 million) will fund operations through the first half of 2028.
- The company has a term loan facility with $25.0 million available at the lenders' sole discretion as of December 31, 2025.
Key Risks:
- Capital Requirements: The company expects to continue incurring significant net losses and will require substantial additional capital to advance clinical trials and commercialization.
- Regulatory Uncertainty: The FDA indicated that ASPEN-06 data was not eligible for accelerated approval given the availability of ENHERTU, necessitating a Phase 3 trial which the company has decided not to pursue in the U.S.
- Intellectual Property: Potential limitations exist regarding European patents (EP 2 429 574 and EP 2 995 315) held by third parties that could impact evorpacept development in certain EU territories.
- Stock Listing: The company previously received a Nasdaq non-compliance notice regarding minimum bid price but regained compliance in September 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $140.4 million raised in February 2026 to sustain operations through mid-2028 given the high burn rate of clinical trials.
- ASPEN-09-Breast Trial Design: Confirm the implications of the single-arm design amendment on future regulatory pathways and potential need for additional comparative data.
- Partnership Status: Monitor progress on potential development partnerships for the gastric cancer program (ASPEN-06) given the decision to halt U.S. registrational efforts.
- Intellectual Property Litigation: Assess the status of the appeal regarding European Patent EP 2 995 315 and its potential impact on European market access.
- Debt Covenants: Review the terms of the term loan agreement, specifically the $25 million discretionary tranche and covenants limiting additional indebtedness.